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1. Introduction
There are many complex relationships between tu-
mour cells and effector cells in the immune system.
These interactions are controlled predominantly by cy-
tokines, either within the tumour environment, or sys-
temically where the effector cells may be stimulated as
a response to the presence of the tumour. Favourable
clinical responses in cancer patients have been shown
to be associated with enhanced cell-mediated immunity
as well as T cell infiltration in tumours. This status
is controlled in part by a predominantly Th1 cytokine
profile e.g. IFNγ, TNFα and IL-12. Conversely, pa-
tients with advancing cancer may have impaired cell-
mediated immunity as a result of an imbalance of Th1
and Th2 cytokines e.g. IL-4 and IL-10 [6,9,15]. Whilst
cytokines have long been known to orchestrate the im-
mune system by allowing communication between reg-
ulatory and effector cells, the pleiotropic nature of these
molecules results in a very complex environment in
which to study any single molecule’s properties.
Several in vitro protocols have been developed,
which aim to closely reflect cytokine production and T
cell function in vivo. However, these assays have been
developed in artificial settings and as such only allow
conclusions to be drawn within a defined context [11].
The aim of this report is to outline the basic proto-
cols and applications for the detection of intracellular
cytokines by flow cytometry, in the context of disease
monitoring.
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2. Methodology
Junge and colleagues [7] detailed a method to study
the intracellular cytokine production of single cells
by flow cytometry, which has become the basis of
many studies. This assay has become an indispens-
able means of evaluating immunotherapy in the patient,
where cytokines responses are postulated to influence
clinical outcome. The basic protocol for the detection
of mitogen-induced cytokine production is outlined in
Protocol 1. A variation on this method, which allows
the detection of cytokines from antigen-specific cells,
has been optimised and is outlined in Protocol 2.
2.1. Protocol 1
Mitogen-induced cytokine production can be de-
tected by flow cytometry as described by Junge et al. [7]
with slight modification [17]. Sodium heparinized
venous blood was diluted with an equal volume of
stimulation medium (RPMI 1640 containing 2 mM L-
glutamine; 10% FCS; 100 µg/ml penicillin; 100 µg/ml
streptomycin; 1 µg/ml Iomomycin; 2.5 ng/ml phorbol
12-myristate 13-acetate (PMA); 10 µg/ml Brefeldin A
(BFA)). 1 ml of diluted blood was aliquoted into 15 ml
conical polypropylene tubes and incubated in a hu-
midified incubator at 37◦C 5% CO2 for 4.5 hr. 1 ml
of unstimulated blood incubated with BFA alone was
also set up as a control. 100 µl aliquots of stimulated
blood were then surfaced stained with CD3-PerCP and
CD8-FITC antibodies at room temperature for 15 min.
Erythrocytes were lysed and leukocytes fixed by the
addition of 2 ml of 1xFACS Lysing Solution (Becton
Dickinson, Oxford, UK) and incubated at room tem-
perature for 10 min. Remaining cells were washed in
2 ml wash buffer (PBS/0.5% BSA/0.1% NaN3), before
permeabilising with 500 µl of 1xFACS permeabilisa-
tion solution (Becton Dickinson, Oxford, UK) and in-
cubating at room temperature for 10 min. The cells
were then washed in 2 ml wash buffer before stain-
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ing cells with the appropriate anti-cytokine antibodies
for 30 min at room temperature. Cells were washed
with 2 ml wash buffer and fixed with 200 µl of CellFix
(Becton Dickinson, Oxford, UK) before analysis on a
FACScan (Becton Dickinson, Oxford, UK). Typically
10,000 events were collected.
2.2. Protocol 2
Antigen-specific cytokine production can also be de-
tected by flow cytometry as described by Waldrop et
al. [16] for PBMC and more recently by Dr. V.C. Maino
(Personal communication) for whole blood. Sodium
heparinized venous blood was aliquoted into 15 ml con-
ical polypropylene tubes at 1 ml per tube. The appro-
priate antigen was added at the optimal concentration
along with anti-CD28 (Becton Dickinson, Oxford, UK)
and anti-CD49d (Becton Dickinson, Oxford, UK) anti-
bodies both at 1 µg/ml final concentration. The blood
was mixed gently before being incubated in 5%CO2 for
2 hr. BFA (10 µg/ml final) was added and the diluted
blood incubated at 37◦C for a further 4 hours. EDTA
(20 mM final) was added and vortexed vigorously to re-
move adherent cells and incubated at room temperature
for 15 min. 100 µl aliquots of stimulated blood were
taken, erythrocytes lysed and leukocytes fixed by the
addition of 2 ml of 1×FACS Lysing Solution (Becton
Dickinson. Oxford, UK) and incubated at room tem-
perature for 10 min. Remaining cells were washed in
2 ml wash buffer (PBS/0.5% BSA/0.1% NaN3), before
permeabilising with 500 µl of 1xFACS permeabilisa-
tion solution (Becton Dickinson. Oxford, UK) and in-
cubated at room temperature for 10 min. The cells were
washed in 2 ml of wash buffer before being stained
for surface CD69-PE, CD4-PerCP and intracellular cy-
tokines simultaneously at room temperature for 30 min
in the dark. The cells were then washed and fixed for
analysis as outlined in the mitogen-stimulated protocol
above. Typically, 50,000 events were collected.
3. Results
The following examples comprise of cytokine data
obtained from 2 patients with malignant melanoma
who received two different immune treatments over
varying time schedules. Patient 1 was injected twice
with BCG (Bacille-Calmette-Gue´rin), which is a non-
specific adjuvant commonly used in the treatment of
bladder cancer. Whilst its application in immunother-
apy has been shown to correlate with cell mediated re-
sponses, there have been marked differences in clinical
outcome of individual patients [15]. Figure 1 represents
the mitogen-induced cytokine (protocol 1) profiles of
the Th1-associated cytokine interferon-γ (IFNγ) and
the Th2-associated cytokine interleukin-4 (IL-4) before
and after the administration of BCG. It is apparent that
there is a significant alteration in the general cytokine
profiles with an increase in the number of IFN( produc-
ing cells and a decrease in IL-4 producing cells, this is
typical of a Th2 to Th1 switch.
Patient 2 was treated with a HLA-A2* binding pep-
tide, specific for a melanoma-associated antigen, over
a period of 6 weeks. Blood samples were tested be-
fore and after treatment using the same peptide in an
antigen-specific cytokine assay (protocol 2). The pres-
ence of peptide, as well as anti-CD28 and anti-CD49d
antibodies, has induced activation of some CD4+ T
cells and the production of IFNγ from a low frequency
of responding cells (Fig. 2).
4. Discussion
To date, the majority of published studies evaluating
cytokine production after immunotherapy have cou-
pled mitogenic stimulation of lymphocytes to responses
at either the mRNA level using reverse transcriptase-
polymerase chain reaction (RT-PCR) analysis, or at the
protein level by ELISA. Significant disadvantages are
associated with both of these techniques. Firstly, RT-
PCR requires isolation of peripheral blood mononu-
clear cells (PBMC), rendering the analysis of small
blood volumes impossible. Secondly, translocational
control methods involved in the regulation of cytokine
gene expression mean that the levels of cytokine RNA
may not accurately reflect the amount of protein syn-
thesised [17]. Thirdly, RT-PCR gives rise to many false
positive results within the context of detecting cytokine
production.
The detection of cytokines at the protein level re-
quires their specific isolation and concentration from
serum or supernatants of experimental cell cultures.
This can also be achieved by the use of specific mono-
clonal anti-cytokine antibodies employed in an ELISA.
However, many molecules, such as β-2-microglobulin,
produced by cells are capable of interfering with the
detection of cytokines by binding to cytokines them-
selves, thus inhibiting their detection by ELISA [3].
Whilst ELISA studies are informative, they can only
give an impression of the bulk cytokine production from
a heterogeneous population of cells. They assume that
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Fig. 1. Intracellular flow cytometry detection of cytokine synthesis from peripheral blood T lymphocytes stimulated following protocol 1 (see
Methods). Cells were selected from a ‘tight’ lymphocyte gate set on the cells forward and side scatter properties, and T cells selected by staining
positive for CD3. The percentages in each quadrant represent percentage of CD8+ (LR, UR) or CD4+ (i.e. CD3+/CD8- (LL, UL) T cells
producing IFN( (A) or IL-4 (B).
all cells of a given phenotype respond in a similar way
under experimental conditions, which is not an accurate
reflection of cytokine expression by individual effector
cells [2,8].
Assays have therefore been developed to study
cytokine production by single effector T cells –
these include immunofluorescence microscopy [14];
ELISpot [1] and limiting dilution analysis [13]. How-
ever, even though all three assays offer additional ben-
efits they involve labour intensive techniques requiring
considerable technical expertise, the result of which
is that the routine examination of single cells is still
greatly restricted. The levels of cytokine production by
individual T cells stimulated following these protocols
is relatively low. This makes the subsequent discrim-
ination between cytokine positive and negative cells
prone to subjective discrepencies. The advent of flow
cytometry has allowed the automated detection of many
thousands of cytokine-secreting cells simultaneously.
The employment of golgi transport inhibitors such as
monensin and brefeldin A allow the concentration of
cytokines within the cell amplifying the detection of
cytokine producing cells. Furthermore, individual cells
may be assessed for secretion of more than 1 cytokine
at once.
In patients receiving inert adjuvants such as BCG,
there may be little point in trying to examine the re-
sponse of lymphocytes to specific antigens. The very
low frequencies of antigen-specific T cells compared
to the vast heterogeneous T cell repertoire mobilised in
response to adjuvants means that there is little chance
of being able to detect subtle changes in their cytokine
profile. A more appropriate assessment of the im-
mune response to immunotherapy may be to examine
alterations in the balance between Th1 and Th2 cy-
tokine production as determined by mitogen-induced
protocol. Likewise, where specific effector cells have
been targeted by antigen-specific immunotherapy, sim-
ply screening for gross changes in the balance between
Th1 and Th2 cytokine production gives us very little
information, as the responding T cells occur at such low
frequencies. The frequency and cytokine profiles of
responding T cells can only be detected and compared
when examined by antigen-specific intracellular flow
cytometry, as the assay is designed to look for changes
at the minute level of individual cells.
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Fig. 2. Intracellular flow cytometry detection of cytokine synthesis from peripheral blood T lymphocytes following protocol 2 (see Methods).
Cells were selected from a ‘tight’ lymphocyte gate set on the cells forward and side scatter properties and T helper cells selected by staining
positive for CD4. The percentages in each quadrant represent percentage of CD69+ (activated) T cells producing IFNγ of unstimulated (A) and
peptide/CD28/CD49d stimulated cells.
When selecting which protocol for detecting cy-
tokine production to use consideration must be made
with respect to the heterogeneity of responding cells.
Many researchers have concluded that, in response to
selected antigens, cytokine synthesis varies between
stimulated cells. They postulate that even these sub-
tle differences may hold the key to detecting positive
immunomodulation [12].
However, there are disadvantages associated with the
detection of intracellular cytokines common to both
protocols. Firstly, the necessity of blocking golgi trans-
port prevents the ability to quantitate cytokine produc-
tion at the single cell level. Secondly, the process
of fixing and permeabilising cells prevents subsequent
functional investigation.
Peptide-MHC tetramers have been developed which
allow the detection and isolation of viable antigen-
specific T cells by flow cytometry. This method can
also be used in conjunction with cytokine detection [4]
however, this approach is limited by the need for HLA
and specific immunogenic peptide determination. An-
other recently developed technology is that of antibody-
antibody conjugates as a cell surface matrix technology.
The conjugates are specific for cell surface CD45 and
cytokine and as such allow the detection of secreted cy-
tokine from specific viable cells which can be isolated
and characterised further [10].
In conclusion, there are now several established
methods for the detection of cytokine production at the
single cell level. Each assay has its own advantages
and disadvantages making the selection of the most ap-
propriate application dependant on the resources and
expertise available. However, the major consideration
in the selection should be the specificity of the assay
in relation to that of the stimulation regime if cytokine
production is to reflect positive clinical outcome, e.g.
vaccination.
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